IBA SA : IBA to Install Four-Room Proton Therapy Solution at Beijing Proton Medical Center
25 Septembre 2016 - 3:00PM
IBA to Install
Four-Room Proton Therapy Solution at Beijing
Proton Medical Center
Louvain-la-Neuve,
Belgium, 25th September
2016 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy
solutions for the treatment of cancer, announces that it has signed
a contract with Medstar (Shanghai) Leasing Co., Ltd, a subsidiary
of Concord Medical Services Holdings Limited ("Concord Medical"),
for the purchase, installation and maintenance of a proton therapy
system. The system will be installed at Beijing Proton Medical
Center and be operated by Beijing Proton Medical Center
Limited.
IBA will equip the hospital with
its Proteus®PLUS*
four-room configuration, including three gantry-rooms and one
fixed-beam room. All rooms will be equipped with IBA's last
generation Pencil Beam Scanning capability. The contract, including
a multi-year comprehensive maintenance contract, is worth more than
70 million EUR and is subjected to financing. IBA expects to book
the order in Q4 2016.
Olivier Legrain,
Chief Executive Officer of IBA commented, "We are delighted to
be enhancing our presence in China, another important indication of
the appeal of our offering in the region. We are also pleased
to be supporting Beijing Proton Medical Center to advance its
vision of bringing proton therapy to more patients in China. IBA's
proton therapy technology has been used to treat more cancer
patients than any other company in the world. This extensive
experience and knowledge of proton therapy technology has allowed
IBA to ensure that more patients are able to access this highly
accurate form of cancer treatment."
Dr. Jianyu Yang,
Chairman and Chief Executive Officer of Concord Medical,
commented: "We are delighted to see Beijing Proton Medical
Center has made a significant breakthrough after so much efforts
had been made in these years. It is Concord Medical's first proton
therapy center in China and we are glad to have IBA as our
equipment vendor. Our partner, China-Japan Friendship Hospital, is
a well-known general hospital in Beijing, with outstanding
scientific research ability and nationwide brand awareness. Going
forward, we will learn from the experience and technology from
other advanced proton centers in the world and are committed to
providing the best treatment for the cancer patients in China. By
carrying out joint clinical research projects with international
peers, we hope to achieve more academic breakthrough in proton
cancer therapy research. "
- END -
Notes to
Editors
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room solutions. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,400 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
* Proteus®PLUS is the
brand name of a Proteus®235
configuration
About Beijing
Proton Medical Center
The Beijing Proton Medical Center is jointly-developed by Concord
Medical Services and China-Japan Friendship Hospital. The 5,000
square meter, international-standards medical facility will be
equipped with radiotherapy and diagnostic equipment including
proton therapy system, linear accelerator, and PET-CT. It will also
provide inpatient services to meet patients' specific needs.
Concord Medical is committed to providing patients with the most
reliable and comprehensive cancer radiotherapy in China
About Concord
Medical
Concord Medical Services Holdings Limited is a leading specialty
hospital management solution provider and operator of the largest
network of radiotherapy and diagnostic imaging centers in China. As
of June 30, 2016, the Company operated a network of 123 centers
with 73 hospital partners that spanned 52 cities and 25 provinces
and administrative regions in China. Under long-term arrangements
with top-tier hospitals in China, the Company provides radiotherapy
and diagnostic imaging equipment and manages the daily operations
of these centers, which are located on the premises of its hospital
partners. The Company also provides ongoing training to doctors and
other medical professionals in its network of centers to ensure a
high level of clinical care for patients. As part of its high-end
cancer hospital development strategy and oversea business
extension, the Company acquired Concord Cancer Hospital, a private
hospital in Singapore in April, 2015.
For further
information please contact:
IBA
Jean-Marc Bothy
Chief Strategy Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas
Ralet
Vice-President Corporate Communication
+32 10 475 890
thomas.ralet@iba-group.com
For media and investor
enquiries:
Consilium Strategic Communications
Jonathan Birt, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+1 917 322 2571
mcarey@RxIR.com
|
Beijing_Proton_Medical_Center_IBA
PR-EN-20160925
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024